Novo Nordisk sees faster profit growth on diabetes drug Ozempic Reuterssource Post navigation Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease | Eli Lilly and Company – Investors | Eli Lilly and Company PRVB stock climbs as FDA proposes labeling for experimental diabetes drug (NASDAQ:PRVB) – Seeking Alpha
